Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TechCrunch | 24.09.2026 02:31Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.
![El Dragón Declares Pasta Noche | Parlor Room [Full Episode]](https://cdn.thefuse.co.za/images2/c/f/9/6/3/cf963048-e33d-36f4-ab21-d829e72a7561-480x270.jpg)